Source disclosure: March 02, 2026, 08:45 JST
MediciNova,Inc. [4875.T]
TOKYO, Mar 02 (Pulse News Wire) – Medicinova,inc. (4875.T) announced today that its Chief Medical Officer (CMO), Kazuko Matsuda, was appointed as Senior Vice President during a board meeting held on February 27, 2026 (U.S.
Time). Matsuda joined MediciNova in 2011 as CMO and became a director in 2019. She has significantly contributed to the advancement of the company's drug development efforts and played a crucial role in guiding the company towards its goals. Her promotion to Senior Vice President reflects her ability to drive further growth and innovation within the organization. Kazuko Matsuda holds a Doctor of Medicine degree from Sapporo Medical University and a Master of Public Health from Harvard Daigaku.
She completed her residency training in pediatrics at Michigan Shuuritsu Daigaku and Roma Rinda Daigaku Shouni Byouin, followed by a fellowship in pediatric infectious diseases at Los Angeles Children’s Hospital/Southern California Daigaku in 2008. Prior to joining MediciNova, she served as Assistant Professor at Southern California Daigaku Keck School of Medicine. MediciNova is a clinical-stage biopharmaceutical company based in the United States, focusing on developing treatments for inflammatory diseases, neurodegenerative disorders, and cancer. Key compounds MN-166 (ibudilast) and MN-001 (tipelukast) are currently undergoing Phase III trials for Amyotrophic Lateral Sclerosis (ALS) and Degenerative Cervical Myelopathy (DCM), while also being evaluated in Phase II trials for glioblastoma and substance dependence. MN-001 is also in Phase II trials targeting lipid abnormalities and non-alcoholic fatty liver disease (NAFLD) caused by diabetes.
AI-translated content. 🟢 Confidence: High See terms • Original filing